Atypical Hemolytic Uremic Syndrome market Forecast. DelveInsight's Atypical Hemolytic Uremic Syndrome Market report offers an in-depth understanding of the ...

A biologic medicine, Ultomiris (ravulizumab) works by inhibiting the complement system, which is thought to play a role in the severe pneumonia that can occur in patients with serious SARS-CoV-2 ...

Alexion already has a newer product to defend the franchise in Ultomiris (ravulizumab), a longer-acting C5 inhibitor that requires dosing every eight weeks while Soliris is given every two weeks.

To prevent the cell destruction seen in PNH, her hematologist started her on a long-term treatment, an infused medication called ravulizumab. PNH is a chronic disease, but she was so determined to ...

Non-transplant PNH therapies include anti-C5 monoclonal antibodies that reduce terminal complement activation (eculizumab, ravulizumab, and crovalimab) and proximal complement pathway inhibitors such ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Cartesian Therapeutics develops mRNA cell therapies for autoimmune diseases, leveraging three modalities: mRNA CAR-T, mRNA MSC, and mRNA in situ. Lead asset Descartes-08 targets myasthenia gravis ...

In England and Wales, MCC vaccine programs resulted in substantial herd immunity, as shown by reductions in serogroup C carriage prevalence and serogroup C disease in unvaccinated individuals ...

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with SMA treated with intrathecal ...

Case Report Overview of Ceftriaxone-Induced Hepatic Panel Abnormalities Discussion Conclusion References Another case report described an 80-year-old man who was hospitalized with painless ...